Last updated on December 2019

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Brief description of study

This is a Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with EGFRvIII-positive glioblastoma. This study will enroll 2 groups of subjects according to disease stage, recurrent disease (Group 1) and maintenance treatment after SoC in newly diagnosed disease (Group 2).

Clinical Study Identifier: NCT03296696

Find a site near you

Start Over

Research Site

Amsterdam, Netherlands
  Connect »